Myriad Genetics, Inc. (MYGN) Forward P/S Multiple

Graphic logo of Myriad Genetics (MYGN)

Myriad Genetics, Inc. (MYGN) stock dynamics rely on patent protection and stringent FDA regulations. However, declining insurance reimbursements and competition are creating pressure, although tighter control over LDT tests could strengthen the leader's position. The projected P/S ratio demonstrates market revenue expectations, where 0.70 sets the current value of the metric, capturing the balance between capitalization and future earnings.

MYGN Myriad Genetics: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 11/14/2026

MYGN (myriad.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Myriad|MYGN - Analyst Median Target
- market capitalization details:
Market Capitalization Myriad Genetics Corp|MYGN - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Myriad Genetics|MYGN - Book Valuation of Business|Market Value to Book Value Ratio myriad.com|MYGN - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Equity Ratio Myriad Genetics, Inc.|MYGN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Myriad Genetics|MYGN - Aggregate Debt Obligations|Debts to Book Capitalization Myriad Genetics Corp|MYGN - Long-Term Debt Volume|Company Short-Term Debts Myriad Genetics|Quick Ratio myriad.com
- business earnings and investment ratios data:
MYGN - Company Profit|Future Profit Myriad Genetics, Inc.|MYGN - Company Value to Net Income|Forward P/E Multiple Myriad|MYGN - Price to Net Income Growth Ratio|EV/EBITDA Multiple Myriad|MYGN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Myriad Genetics|MYGN - Earnings per share for the last 12 months|Quarterly EPS earnings growth myriad.com|MYGN - Earnings per share growth rate in current year|Expected earnings per share growth for next year Myriad Genetics, Inc.
- sales volume and revenue indicators:
MYGN - Company Total Sales|Projected Sales Volume Myriad|MYGN - Price-to-Revenue Coefficient|Forward P/S Multiple Myriad Genetics Inc
Summary company analysis:Myriad MYGN
Manufactured products of Myriad Genetics, Inc.

Investors must find a balance between operating expenses and capital efficiency at Myriad Genetics, Inc. (MYGN). The company's business model depends on insurance coverage and the control of legal expenses amid growing demand for genetic testing. Analyzing the forward price-to-sales ratio, we see the current market capitalization relative to expected annual sales. This indicator determines the market value of every dollar of future revenue, signaling the extent of expectations priced into the company's stability.

Analysis of competing companies

Forward P/S Multiple CAI (Caris Corp)|Market Cap to Expected Sales Ratio Guardant360 (GH)|veracyte.com - Forward P/S Multiple|Market Cap to Expected Sales Ratio celcuity.com CELC|GRAIL Inc (GRAL) - Price-to-Projected Revenue Ratio|CSTL - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BNR|Price-to-Projected Revenue Ratio VNRX|Forward P/S Multiple BDSX|PRPO (Precipio, Inc.) - Forward Price to Sales|Forward P/S Multiple CHEK (Check-Cap)|Market Cap to Expected Sales Ratio mainzbiomed.com (MYNZ)|OncoCyte Inc - Forward P/S Multiple